Used in pharmaceutical research as a potent and selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK9, which plays a key role in transcription regulation. This compound shows promise in oncology for disrupting cancer cell proliferation and survival by blocking the transcriptional machinery in tumor cells. It is investigated for its antitumor activity in hematological malignancies and solid tumors. Due to its ability to induce apoptosis and suppress RNA synthesis, it serves as a valuable tool compound in mechanistic studies of transcriptional control and kinase signaling pathways. Its structure allows for high binding affinity and selectivity, making it a candidate for development into targeted cancer therapies.